Quest for Growth participates in € 60 million funding round for Confo Therapeutics, advancing innovative therapies

Quest for Growth, alongside with Capricorn Health-tech Fund, has invested in Confo Therapeutics, a clinical-stage company and leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), situated in Ghent, Belgium.

Capricorn Health-tech Fund, which is also managed by Capricorn Partners, has been a co-founder of Confo Therapeutics in 2015. Quest for Growth now joins a new financing round with a direct investment of EUR 1 million. The new investment round was led by Ackermans & van Haaren (AvH) and welcomed new transatlantic investment company Driehaus Capital Management, situated in the US. Existing shareholders participated in this round for EUR 28 million in total, with an investment of EUR 4.6 million from the Capricorn Health-tech Fund. Quest for Growth is an important shareholder in Capricorn Health-tech Fund bringing its direct and indirect exposure in Confo Therapeutics to a fully diluted level of 3.48%.